Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women

  title={Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women},
  author={Nicoletta Provinciali and Chen S. Suen and Barbara K. Dunn and Andrea Decensi},
  journal={Expert Review of Clinical Pharmacology},
  pages={1263 - 1272}
ABSTRACT Introduction: Raloxifene is an estrogen receptor modulator which competes with estrogens for binding to the estrogen receptor. Based on the results of the STAR (Study of Tamoxifen And Raloxifene) trial, raloxifene has been approved by the U.S. Food and Drug Administration for the reduction of breast cancer (BC) risk in postmenopausal women at increased risk. Areas covered: This analysis reviews the activity of raloxifene and the clinical trials for non-BC indications which led to… 
Combined Raloxifene and Letrozole for Breast Cancer Patients.
Pharmacotherapy for schizophrenia in postmenopausal women
Estrogen modulators may not help all symptoms of schizophrenia but are, nevertheless, relatively safe and, when used as adjuncts, help to keep antipsychotic doses low, thus reducing the side effect burden.
Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling
Inhibition of ERβ and the IL-6/gp130/STAT3 signaling pathway by raloxifene leads to potent reduction of PDAC growth in vitro and in vivo and is suggested to serve as an attractive therapeutic option for PDAC patients expressing the ERβ isotype.
Chemoprevention : Using Drugs and Nutrients to Decrease Cancer Risk
This review addresses selected areas that are central to the state-of-the-art of cancer prevention science, and focuses on active intervention with measures involving pharmaceutical and immunological agents.
Nuclear receptors: recent drug discovery for cancer therapies.
This article overviews NR-based drug discovery in cancer and related resistance mechanisms, focusing on novel strategies for targeting well-established NR targets, including ERα, AR, the glucocorticoid receptor and the progesterone receptor, as well as opportunities to target other NRs that are attracting interest in immuno-oncology.
Drug repurposing for breast cancer therapy: Old weapon for new battle
Metabolic Bone Diseases and New Drug Developments
A large amount of research literature suggests that balanced nutrition and balanced periodic supplementation of calcium, phosphate, and vitamin D can improve re-absorption and the regrowth of bones, and inhibit the formation of skeletal fractures, except in the case of hereditary bone diseases.
Risk Assessment for Hereditary Breast and Ovarian Cancers
  • Biology
  • 2018
Risk factors for hereditary breast and ovarian cancers include a family history with highly penetrant mutations in genes such as BRCA1 and BRCa2, moderately penetrant mutation in other genes, as well as more common genomic variants, including single nucleotide polymorphisms, associated with modest effect sizes.


Review on raloxifene: profile of a selective estrogen receptor modulator.
  • M. Heringa
  • Medicine, Biology
    International journal of clinical pharmacology and therapeutics
  • 2003
It has been proven that raloxifene decreases levels of both bone formation markers and bone resorption markers in postmenopausal women and preserves the bone mineral density at most skeletal sites in these women.
Clinical effects of raloxifene hydrochloride in women.
Raloxifene is now available as an alternative to estrogen replacement therapy for women at risk for osteoporosis and is reviewed during the past two decades on the clinical effects of ralox ifene in women.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
Among postmenopausal women with osteoporosis, the risk of invasive breast cancer was decreased by 76% during 3 years of treatment with raloxifene, mainly in the United States and Europe.
Pharmacokinetics of raloxifene and its clinical application.
  • D. Hochner-Celnikier
  • Medicine, Biology
    European journal of obstetrics, gynecology, and reproductive biology
  • 1999
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis
  • E. Lewiecki
  • Medicine, Biology
    Therapeutics and clinical risk management
  • 2009
Clinical trials show that lasofoxifene is generally well tolerated with mild to moderate adverse events that commonly resolve even with drug continuation, and it is approved for the treatment of postmenopausal women at increased risk for fracture in some countries and is in the regulatory review process in others.
Use of SERMs for treatment in postmenopausal women
Raloxifene use in clinical practice: efficacy and safety
Based on its approved indications, it is appropriate to prescribe raloxifene to prevent or treat osteoporosis, as well as to reduce the risk of invasive breast cancer in PMW with osteoporeosis or at high risk of breast cancer.
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
The reduction in invasive breast cancer incidence continues beyond 4 years of raloxifene treatment in postmenopausal women with osteoporosis, and no new safety concerns related to ral oxifene therapy were identified during CORE.